Luke O’Neill joins Open Orphan spin-off ahead of pharma firm’s IPO

Ambitions are high for Poolbeg Pharma, which will develop drugs to fight infectious diseases

20th June, 2021
Luke O’Neill joins Open Orphan spin-off ahead of pharma firm’s IPO
Professor Luke O’Neill, the immunologist, is a non-executive director of Poolbeg Pharma and a member of the company’s scientific advisory board. Picture: Barry Cronin

Luke O’Neill, the well-known immunologist, has joined the board of the fledgling Poolbeg Pharma which is preparing for a stock market launch in coming weeks.

Poolbeg Pharma is a newly launched spin-off of Open Orphan, the life sciences business co-founded by veteran financier Cathal Friel, and will specialise in developing drugs to treat infectious diseases.

O’Neill is a non-executive director and a member of the company’s scientific advisory board.

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Related Stories

Pinterest doubles Irish workforce as revenues surge by €100m

Turnover down 50% at River Island as pandemic hits in-store trading

Companies Donal MacNamee 10 hours ago

Nestlé cuts value of stake in shrinking infant formula arm by €260m

US medtech behemoth signals intent to commit to Ireland